VIDEO: Newly approved nonhormonal menopausal therapy effective for those avoiding HT

PHILADELPHIA — In this video exclusive, Nanette Santoro, MD, discussed efficacy for different groups of women of a nonhormonal neurokinin 3 receptor antagonist recently approved by the FDA to treat moderate to severe hot flashes.

Santoro, who is a professor and the E. Stewart Taylor Chair of OB/GYN at the University of Colorado School of Medicine, described study results for use of fezolinetant (Veozah, Astellas Pharma) by women who cannot or do not want to use hormonal therapies for symptoms of menopause, including sleep.

“What we saw was a similar trend in all of these groups in that they seemed to get similar relief from fezolinetant, particularly at the FDA-approved dose,” Santoro said.